Autophagy Inhibition in BRAF-Driven Cancers
Several BRAF-driven cancers, including advanced BRAF<sup>V600E/K</sup>-driven melanoma, non-small-cell lung carcinoma, and thyroid cancer, are currently treated using first-line inhibitor combinations of BRAF<sup>V600E</sup> plus MEK1/2. However, despite the success of this v...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/14/3498 |